Use of direct oral anticoagulants in ICU patients. Part I - Applied pharmacology
Direct oral anticoagulants (DOACs) have revolutionized the field of anticoagulation in the last decade, mainly due to their fixed dosing, rapid onset of anticoagulant effect, and non-inferiority to vitamin K antagonists for both efficacy and safety. Also, the availability of specific and non-specific reversal agents makes these drugs popular. However, in critically ill patients, significant alterations in drug pharmacokinetics and pharmacodynamics might occur due to various ongoing pathophysiological derangements like decreased gastrointestinal absorption, increased volume of distribution, and impaired renal and/or hepatic function. Insight into these changes is essential regarding the safe and effective use of DOACs in critically ill patients. The current article is a narrative review on the use of DOACs in intensive care unit patients, covering 'Applied pharmacology'; the second article in the series covers 'Clinical evidence'.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
Anaesthesiology intensive therapy - 53(2021), 5 vom: 01., Seite 429-439 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wahab, Abdul [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anticoagulants |
|---|
| Anmerkungen: |
Date Completed 08.03.2022 Date Revised 19.05.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.5114/ait.2021.110607 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM333539354 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM333539354 | ||
| 003 | DE-627 | ||
| 005 | 20231225221842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5114/ait.2021.110607 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1111.xml |
| 035 | |a (DE-627)NLM333539354 | ||
| 035 | |a (NLM)34816705 | ||
| 035 | |a (PII)45600 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wahab, Abdul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use of direct oral anticoagulants in ICU patients. Part I - Applied pharmacology |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.03.2022 | ||
| 500 | |a Date Revised 19.05.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Direct oral anticoagulants (DOACs) have revolutionized the field of anticoagulation in the last decade, mainly due to their fixed dosing, rapid onset of anticoagulant effect, and non-inferiority to vitamin K antagonists for both efficacy and safety. Also, the availability of specific and non-specific reversal agents makes these drugs popular. However, in critically ill patients, significant alterations in drug pharmacokinetics and pharmacodynamics might occur due to various ongoing pathophysiological derangements like decreased gastrointestinal absorption, increased volume of distribution, and impaired renal and/or hepatic function. Insight into these changes is essential regarding the safe and effective use of DOACs in critically ill patients. The current article is a narrative review on the use of DOACs in intensive care unit patients, covering 'Applied pharmacology'; the second article in the series covers 'Clinical evidence' | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a critically ill | |
| 650 | 4 | |a drug-drug interaction | |
| 650 | 4 | |a oral anticoagulant. | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 4 | |a renal dysfunction | |
| 650 | 4 | |a intensive care unit | |
| 650 | 7 | |a Anticoagulants |2 NLM | |
| 700 | 1 | |a Patnaik, Rupali |e verfasserin |4 aut | |
| 700 | 1 | |a Gurjar, Mohan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anaesthesiology intensive therapy |d 2012 |g 53(2021), 5 vom: 01., Seite 429-439 |w (DE-627)NLM22116264X |x 1731-2531 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2021 |g number:5 |g day:01 |g pages:429-439 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5114/ait.2021.110607 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2021 |e 5 |b 01 |h 429-439 | ||